AVBP

ArriVent BioPharma, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

2Trials in this database

1Recorded changes · last 12 months

Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source

Trial	Sponsor	Phase	Status	Primary completion
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550	AVBP	Phase 3	Active not recruiting	2025-08-15Estimated
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997	AVBP	Phase 3	Recruiting	2029-02Estimated

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

AVBPActive not recruitingPrimary completion: 2025-08-15 · Estimated

Trial details

Registry ID: NCT05607550
Phase: Phase 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

AVBPRecruitingPrimary completion: 2029-02 · Estimated

Trial details

Registry ID: NCT07185997
Phase: Phase 3

Latest recorded trial changes

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT07185997 · ArriVent BioPharma, Inc.

Posted 2025-10-23 · 1 field changed

Recruitment status

Recorded edit

− Previous value

Not yet recruiting

+ Updated value

Recruiting

Check registry source